The Identification of Novel Prognostic Markers in Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01002560|
Recruitment Status : Unknown
Verified October 2009 by Royal Marsden NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : October 27, 2009
Last Update Posted : October 27, 2009
|Condition or disease|
Background - The Royal Marsden Hospital and the Institute of Cancer Research constitute the largest comprehensive cancer centre in Europe. In addition to an in-house drug development program, phase I - phase III clinical trials of novel anti-cancer agents are hosted. In order to investigate the optimal use of novel molecularly targeted agents, access to clinical tumour samples is needed in order to determine which particular cancer type expresses a molecular "signature" that may indicate potential therapeutic utility. Understanding such signatures should accelerate the registration of new drugs for routine cancer therapy; offering the potential of selecting those patients with tumour types most likely to benefit from therapy. Furthermore, new insights into disease biology may be gained.
Main research question/ objective - Are there features of primary melanoma or lymph node metastases that predict subsequent clinical outcome better than existing markers?
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Observational Model:||Case Control|
|Official Title:||Novel Prognostic Markers in Melanoma: a Protocol for the Analysis of Paraffin-embedded Tumour Samples|
|Study Start Date :||December 2008|
|Estimated Primary Completion Date :||December 2009|
|Estimated Study Completion Date :||December 2009|
|Malignant melanoma tumour tissue|
Benign pigmented lesions & other skin cancers
Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
- Given that the nature of the research is qualitative, there is no primary outcome measure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01002560
|Contact: Professor Martin Goreemail@example.com|
|Royal Marsden NHS Foundation Trust||Recruiting|
|Sutton, Surrey, United Kingdom, SM2 5PT|
|Principal Investigator:||Professor Martin Gore||Royal Marsden NHS Foundation Trust|